Hints and tips:
...Novavax’s Stanley Erck will be replaced by John C Jacobs, most recently chief executive at Harmony Biosciences, this month; CureVac’s Franz-Werner Haas will be succeeded by Alexander Zehnder, a Sanofi veteran...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...Stanley Erck, Novavax chief executive, said the change to the company’s revenue forecasts reflected a collapse in demand from two markets: the US and Covax, the global vaccine initiative that aims to deliver...
...Luke Hildyard, director of the High Pay Centre, a London-based think-tank. said chief executives at top Wall Street banks like JPMorgan, Goldman Sachs, Morgan Stanley and Bank of America still earned more...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Chief executive Stanley Erck said at the time “all the manufacturing issues that we went through have been resolved”. Novavax’s regulatory filings so far have been for the primary two doses....
...Speaking at the Morgan Stanley Global Healthcare Conference on Tuesday, D’Amelio added that the putative timeline assumed “all of the data is positive”....
...the trading day were intense, with gauges of volatility surging to the highest levels since since October 2020, ahead of the US election and results of the effectiveness of vaccines being developed by Pfizer...
...The UK, where messenger RNA shots such as that from BioNTech/Pfizer have been deployed in a booster campaign, has a deal for up to 60m Novavax shots....
...Stanley Perlman, professor of microbiology and immunology at the University of Iowa, said: “I support this [application] because we’ve already approved it for Pfizer and I don’t see how we can possibly not...
...Stanley Erck, Novavax chief executive, said it was likely to be the first of many authorisations announced in the coming weeks and months....
...Last month, Pfizer said it planned to apply for approval of its third dose in August....
...Pfizer, AbbVie and Bristol-Myers Squibb all have blockbuster drugs due to lose exclusivity soon and have recently sealed multibillion-dollar deals....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...The vaccine could fetch nearly $13bn in global sales next year, which would be evenly split between Pfizer and BioNTech, says Morgan Stanley....
...The aborted trials include Pfizer and Johnson & Johnson’s scrapped study in 2012 and Merck’s failed trial in 2017....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Stanley Erck, Novavax chief executive, thanked Operation Warp Speed, which gave the company one of its largest grants to vaccine makers....
...stock fell 5.9 per cent to £76.78 on Monday as investors digested the deal; Goldman Sachs — the press release announcing the deal doled out financial advisory credit to its Wall Street neighbours Morgan Stanley...
...Vaccines from BioNTech/Pfizer and Moderna have received emergency approval, while the regulator’s vaccine advisory group is set to meet to discuss the shot from Johnson & Johnson at the end of the month....
...Covid-19 vaccines from Moderna and BioNTech/Pfizer have been shown to work against the B.1.1.7 variant in laboratory tests....
...Interim data have shown that its vaccine has an efficacy rate up there with the shots developed by BioNTech/Pfizer and Moderna, based on revolutionary messengerRNA technology....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Novavax joins big pharmaceutical companies Johnson & Johnson, Pfizer, Merck and AstraZeneca in Operation Warp Speed, a US health department project touted by President Donald Trump, which aims to accelerate...
International Edition